Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2007

View Archived Issues

Crucell's West Nile vaccine meets phase I study endpoints

Nasalfent begins phase III program in breakthrough cancer pain

New phase I/II trial under way for TNFerade in head and neck cancer

IND acceptance for SPC/ENZ-2968 triggers milestone payment

Aranesp increases risk of death in cancer patients not receiving treatment

Novel inhibitor of protein-protein interactions in the Wnt pathway suppresses tumor growth in vivo

Oral entry inhibitor SP-10 shows antiviral activity in HCV

VRX-480773: a novel NNRTI with activity against efavirenz-resistant HIV

LAB International closes PharmaForm acquisition

Recent patents describe new agents for musculoskeletal and connective tissue disorders

Recent patents report novel therapeutic agents for HIV infection

New agents for schizophrenia and depression disclosed in recent patents

Targeting orexin receptors may be useful to treat sleep disorders

Yaz approved to treat acne in women

Promising phase II findings for INGN-225 in small cell lung cancer

GSK files prepandemic influenza vaccine in E.U.

Sunesis to advance phase II SCLC study of SNS-595 into second stage

Phase II trial explores topical AVR-118 as wound healing agent

RPI-78M begins phase IIb study in adrenomyeloneuropathy

Intravenous administration approved for Vidaza

Phase II enrollment open for glufosfamide in platinum-resistant ovarian cancer

Preliminary findings from phase IIb asthma study of IPL-512,602

DiabeCell cleared for Russian study in type 1 diabetes

Lexicon changes name, refocuses operations on drug discovery and development

Mirena approved in Japan

Pariet approved in Japan for H. pylori eradication

Relenza approved in Japan for influenza prophylaxis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.